"N" SARS-CoV-2 Nucleocapsid mRNA
- Speed your studies with ready-to-transfect mRNA
- Transiently express the native (not codon optimized) SARS-CoV-2 nucleocapsid protein
- Stable SARS-CoV-2 nucleocapsid protein expression is also available as a stable cell line, pre-packaged transduction-ready lentivirus, and ready-to-package lentivector
Products
Catalog Number | Description | Size | Price | Quantity | Add to Cart | |||
---|---|---|---|---|---|---|---|---|
CVD19-420A-1 | “N” SARS-CoV-2 Nucleocapsid mRNA (10 µg, Transfection-ready) | 10 µg | $340 |
|
||||
CVD19-425A-1 | “N” SARS-CoV-2 Nucleocapsid mRNA (20 µg, Transfection-ready) | 20 µg | $485 |
|
Overview
Overview
Advance your COVID-19 studies with SBI With transfection-ready "N" SARS-CoV-2 Nucleocapsid mRNA, you can go right to studying the native SARS-CoV-2 nucleocapsid protein from the original Wuhan-1 strain. The "N" SARS-CoV-2 Nucleocapsid mRNA delivers robust transient expression to support a range of nucleocapsid protein studies.- Speed your studies with a ready-to-transfect mRNA
- Transiently express the native (not codon optimized) SARS-CoV-2 nucleocapsid protein
- Stable SARS-CoV-2 nucleocapsid protein expression is also available as a stable cell line, pre-packaged transduction-ready lentivirus, and ready-to-package lentivector
Catalog Number | Product name |
---|---|
CVD19-100PA/VA-1 | ACE2 Expression Lentivector, pCDH-CMV-ACE2-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
CVD19-140PA/VA-1 | NRP1 Expression Lentivector, pCDH-CMV-NRP1-EF1α-Neo (Plasmid or Pre-packaged Lentivirus) |
CVD19-120PA/VA-1 | SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, pCDH-CMV-SARS-CoV-2-N-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
CVD19-130PA/VA-1 | SARS-CoV-2 Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-S-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
CVD19-135PA/VA-1 | SARS-CoV-2 Humanized Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-hS-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
CVD19-200A-1 | HEK293 ACE2 Stable Cell Line |
CVD19-260A-1 | HEK293-ACE2-NRP1 Overexpression Stable Cell Line |
CVD19-220A-1 | HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line |
CVD19-420A-1 CVD19-425A-1 | "N" SARS-CoV-2 Nucleocapsid mRNA |
CVD19-430A-1 CVD19-435A-1 | "S" SARS-CoV-2 Spike Glycoprotein mRNA |
CVD19-440A-1 CVD19-445A-1 | "S" SARS-CoV-2 Spike Omicron mRNA |
References
How It Works
Supporting Data
Supporting Data
"N" SARS-CoV-2 Nucleocapsid mRNA is of high-quality
The high quality of the "N" SARS-CoV-2 Nucleocapsid mRNA can be seen in Figure 1, which shows that the in vitro transcribed mRNA migrates as a single species on a 1.5% denaturing agarose gel.
"N" SARS-CoV-2 Nucleocapsid mRNA is well expressed in HEK293T cells
To demonstrate the robust expression of the "N" SARS-CoV-2 Nucleocapsid mRNA, we transfected 1 µg into HEK293T cells and isolated total protein after two days. We analyzed 15 µg of total protein via western blot, probing for both the nucleocapsid protein and β-actin. The high expression of nucleocapsid protein can be seen in Figure 2.
FAQs
Resources
Citations
Related Products
Products
Catalog Number | Description | Size | Price | Quantity | Add to Cart | |||
---|---|---|---|---|---|---|---|---|
CVD19-420A-1 | “N” SARS-CoV-2 Nucleocapsid mRNA (10 µg, Transfection-ready) | 10 µg | $340 |
|
||||
CVD19-425A-1 | “N” SARS-CoV-2 Nucleocapsid mRNA (20 µg, Transfection-ready) | 20 µg | $485 |
|
Overview
Overview
Advance your COVID-19 studies with SBI With transfection-ready "N" SARS-CoV-2 Nucleocapsid mRNA, you can go right to studying the native SARS-CoV-2 nucleocapsid protein from the original Wuhan-1 strain. The "N" SARS-CoV-2 Nucleocapsid mRNA delivers robust transient expression to support a range of nucleocapsid protein studies.- Speed your studies with a ready-to-transfect mRNA
- Transiently express the native (not codon optimized) SARS-CoV-2 nucleocapsid protein
- Stable SARS-CoV-2 nucleocapsid protein expression is also available as a stable cell line, pre-packaged transduction-ready lentivirus, and ready-to-package lentivector
Catalog Number | Product name |
---|---|
CVD19-100PA/VA-1 | ACE2 Expression Lentivector, pCDH-CMV-ACE2-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
CVD19-140PA/VA-1 | NRP1 Expression Lentivector, pCDH-CMV-NRP1-EF1α-Neo (Plasmid or Pre-packaged Lentivirus) |
CVD19-120PA/VA-1 | SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector, pCDH-CMV-SARS-CoV-2-N-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
CVD19-130PA/VA-1 | SARS-CoV-2 Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-S-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
CVD19-135PA/VA-1 | SARS-CoV-2 Humanized Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-hS-EF1α-Puro (Plasmid or Pre-packaged Lentivirus) |
CVD19-200A-1 | HEK293 ACE2 Stable Cell Line |
CVD19-260A-1 | HEK293-ACE2-NRP1 Overexpression Stable Cell Line |
CVD19-220A-1 | HEK293 "N" SARS-CoV-2 Nucleocapsid Overexpression Stable Cell Line |
CVD19-420A-1 CVD19-425A-1 | "N" SARS-CoV-2 Nucleocapsid mRNA |
CVD19-430A-1 CVD19-435A-1 | "S" SARS-CoV-2 Spike Glycoprotein mRNA |
CVD19-440A-1 CVD19-445A-1 | "S" SARS-CoV-2 Spike Omicron mRNA |
References
How It Works
Supporting Data
Supporting Data
"N" SARS-CoV-2 Nucleocapsid mRNA is of high-quality
The high quality of the "N" SARS-CoV-2 Nucleocapsid mRNA can be seen in Figure 1, which shows that the in vitro transcribed mRNA migrates as a single species on a 1.5% denaturing agarose gel.
"N" SARS-CoV-2 Nucleocapsid mRNA is well expressed in HEK293T cells
To demonstrate the robust expression of the "N" SARS-CoV-2 Nucleocapsid mRNA, we transfected 1 µg into HEK293T cells and isolated total protein after two days. We analyzed 15 µg of total protein via western blot, probing for both the nucleocapsid protein and β-actin. The high expression of nucleocapsid protein can be seen in Figure 2.